Sera Prognostics, Inc. (SERA)
- Previous Close
9.79 - Open
9.62 - Bid 9.72 x 100
- Ask 9.82 x 100
- Day's Range
9.50 - 9.80 - 52 Week Range
1.52 - 11.32 - Volume
66,002 - Avg. Volume
231,547 - Market Cap (intraday)
316.151M - Beta (5Y Monthly) 1.49
- PE Ratio (TTM)
-- - EPS (TTM)
-1.16 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
seraprognostics.com55
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: SERA
Performance Overview: SERA
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SERA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SERA
Valuation Measures
Market Cap
316.15M
Enterprise Value
268.93M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
994.14
Price/Book (mrq)
4.51
Enterprise Value/Revenue
878.85
Enterprise Value/EBITDA
-7.62
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-23.50%
Return on Equity (ttm)
-42.86%
Revenue (ttm)
306k
Net Income Avi to Common (ttm)
-36.24M
Diluted EPS (ttm)
-1.16
Balance Sheet and Cash Flow
Total Cash (mrq)
49.08M
Total Debt/Equity (mrq)
2.65%
Levered Free Cash Flow (ttm)
-14.85M